ReviewCurrent cancer drug targets2025

Beyond CTLA-4 and PD-1: Novel Insights into MAO-A as a Next Generation Immune Checkpoint Modulator for Cancer Immunotherapy.

Prajna Maity et al.PubMed ↗Publisher ↗

No numbers read from the abstract.